Quote | Chiasma Inc. (NASDAQ:CHMA)
|Last Trade Date Time:||08/05/2021 04:41:57 am|
News | Chiasma Inc. (NASDAQ:CHMA)
Six multi-billion dollar deals announced last week. VICI Properties acquires MGM Growth Properties for $17.2 billion. Veoneer receives a superior bid from Qualcomm. For further details see: Merger Arbitrage Mondays - Veoneer Receives A Superior Bid From Qualcomm
19 new deals announced in the month of July. Thoma Bravo acquires Medallia. Aon and Willis Towers Watson terminated their business combination agreement. For further details see: Merger Arbitrage Mondays - Thoma Bravo Announces 2 Large Deals In A Single Month ...
Message Board Posts | Chiasma Inc. (NASDAQ:CHMA)
|whytestocks: $CHMA News Article - Chiasma to Present Encore and New Data from MPOWERED(TM) Phase 3 T||whytestocks||investorshangout||05/20/2021 8:40:50 PM|
|* * $CHMA Video Chart 05-05-2021 * *||ClayTrader||investorshub||05/05/2021 8:39:10 PM|
|whytestocks: $CHMA News Article - Chiasma Merger Investigation: Halper Sadeh LLP Announces Investiga||whytestocks||investorshangout||05/05/2021 3:55:47 PM|
|Fool was right!||swampboots||investorshub||05/05/2021 3:50:12 PM|
|whytestocks: $CHMA News Article - Chiasma Reports First Quarter Financial Results and Announced Agre||whytestocks||investorshangout||05/05/2021 2:15:49 PM|
Chiasma Inc. Company Name:
CHMA Stock Symbol:
Chiasma Inc. Website:
Pulmatrix appoints Director Anand Varadan PR Newswire LEXINGTON, Mass. , July 27, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and...
NEEDHAM, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives ...
NEEDHAM, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”) today presented patient-reported outcomes (PROs) data from its MPOWERED™ Phase 3 trial demonstrating that study patients with acromegaly reported si...